The Archive · 2 posts
Innovative cancer solutions! 🔬 Scancell Holdings Plc (SCLP) leads in immunotherapies, traded on LSE. A biotech game-changer! 🚀
Scancell's proposed Neuphoria merger could unlock Nasdaq access and fund Phase 3 development, but dilution and execution risks are substantial.
July 23, 2026
Showing 1 of 2 posts
Scancell's iSCIB1+ shows 78% 11-month PFS in advanced melanoma, with Modi-1 signals and cash runway into H2 2026. Key Phase 2 data and financial results.
JoshuaSeptember 11, 2025